Managing CDKi Adverse Events

CE / CME

Managing AEs With CDK4/6 Inhibitors to Promote Adherence and Persistence to Oral Therapy in Your Practice

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: February 18, 2025

Expiration: August 17, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 5: Elevated LFT With Ribociclib



  • 55-yr-old woman was recently diagnosed with metastatic ER+/HER2- breast cancer

  • Disease recurrence 2 yr after completing adjuvant endocrine therapy with asymptomatic bone-only disease

  • 4 wk ago, she began receiving first-line letrozole and ribociclib (600 mg daily, 3 wk on, 1 wk off)

  • Laboratory monitoring at C2D1 shows LFTs are now 5x ULN (grade 3 hepatotoxicity); she is otherwise asymptomatic; ECG is stable 

Which of the following is optimal management for this patient’s grade 3 LFT?